Abstract
We report the case of a 25-year-old patient who became pregnant during ustekinumab therapy. Treatment was suspended immediately after pregnancy had been confirmed. The patient had an uneventful pregnancy and her child is currently 14 months old, with adequate development to her age. Four reports of pregnancy during ustekinumab treatment have been reported and one resulted in miscarriage.
References
1.
Fotiadou C, Lazaridou E, Sotiriou E, Ioannides D: Spontaneous abortion during ustekinumab therapy. J Dermatol Case Rep 2012;6:105-107.
2.
Andrulonis R, Ferris LK: Treatment of severe psoriasis with ustekinumab during pregnancy. J Drugs Dermatol 2012;11:1240-1241.
3.
Sheeran C, Nicolopoulos J: Pregnancy outcomes of two patients exposed to ustekinumab in the first trimester. Australas J Dermatol 2014;55:235-236.
4.
Alsenaid A, Prinz JC: Inadvertent pregnancy during ustekinumab therapy in a patient with plaque psoriasis and impetigo herpetiformis. J Eur Acad Dermatol Venereol DOI: 10.1111/jdv.12872.
5.
Verstappen SM, King Y, Watson KD, Symmons DP, Hyrich KL: Anti-TNF therapies and pregnancy: outcome of 130 pregnancies in the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2011;70:823-826.
6.
Puig L, Barco D, Alomar A: Treatment of psoriasis with anti-TNF drugs during pregnancy: case report and review of the literature. Dermatology 2010;220:71-76.
7.
Ben-David G, Sheiner E, Hallak M, Levy A: Pregnancy outcome in women with psoriasis. J Reprod Med 2008;53:183-187.
8.
Guven MA, Coskun A, Ertas IE, Aral M, Zencirci B, Oksuz H: Association of maternal serum CRP, IL-6, TNF-alpha, homocysteine, folic acid and vitamin B12 levels with the severity of preeclampsia and fetal birth weight. Hypertens Pregnancy 2009;28:190-200.
9.
Cohen-Barak E, Nachum Z, Rozenman D, Ziv M: Pregnancy outcomes in women with moderate-to-severe psoriasis. J Eur Acad Dermatol Venereol 2011;25:1041-1047.
10.
Lédée-Bataille N, Dubanchet S, Coulomb-L'hermine A, Durand-Gasselin I, Frydman R, Chaouat G: A new role for natural killer cells, interleukin (IL)-12, and IL-18 in repeated implantation failure after in vitro fertilization. Fertil Steril 2004;81:59-65.
11.
Description from FDA NDA review document, http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/125261s000_OtherR.pdf.
12.
Martin PL, Sachs C, Imai N, Tsusaki H, Oneda S, Jiao Q, Treacy G: Development in the cynomolgus macaque following administration of ustekinumab, a human anti-IL-12/23 p40 monoclonal antibody, during pregnancy and lactation. Birth Defects Res B Dev Reprod Toxicol 2010;89:351-363.
13.
European Medicines Agency: Stelara, European Public Assessment Report. EPARs for authorised medicinal products for human use. 2009. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000958/human_med_001065.jsp&mid=WC0b01ac058001d124.
14.
Data on File. Reports of pregnancy with ustekinumab: STE/Inj/DoF/Sep2010/EMEA001. 2010, Janssen.
15.
Cheent K, Nolan J, Shariq S, Kiho L, Pal A, Arnold J: Case report: Fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn's disease. J Crohns Colitis 2010;4:603-605.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
